Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients

被引：1
作者：
Barth, Claire [1 ]
Naveau, Louise [1 ]
Touboul, Emmanuel [1 ]
Perie, Sophie [2 ]
Bamogho, Edith [1 ]
Haberer-Guillerm, Sophie [1 ]
Schlienger, Michel [1 ]
St Guily, Jean Lacau [2 ]
Huguet, Florence [1 ]
机构：
[1] Univ Paris 06, Tenon Hosp, HUEP, Dept Radiat Oncol, Paris, France
[2] Univ Paris 06, Tenon Hosp, HUEP, Dept Head & Neck Surg, Paris, France
来源：
ANTI-CANCER DRUGS | 2016年 / 27卷 / 04期
关键词：
vinorelbine; head and neck cancer; chemotherapy; recurrent; metastatic; PLATINUM-BASED CHEMOTHERAPY; PHASE-II TRIAL; METASTATIC HEAD; RECURRENT; CANCER; CARBOPLATIN; PACLITAXEL; CISPLATIN; CETUXIMAB; METHOTREXATE;
D O I：
10.1097/CAD.0000000000000333
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board's decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3-4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.
引用
收藏
页码：349 / 352
页数：4
相关论文
共 50 条
  • [21] Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
    Hoell, Pascale Alicia
    Elsayad, Khaled
    Berssenbruegge, Hendrik
    Hering, Dominik
    Kittel, Christopher
    Kleinheinz, Johannes
    Bleckmann, Annalen
    Evers, Georg
    Wardelmann, Eva
    Rudack, Claudia
    Eich, Hans Theodor
    ANTICANCER RESEARCH, 2023, 43 (03) : 1255 - 1263
  • [22] Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck
    Machiels, Jean-Pascal
    Schmitz, Sandra
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (03) : 359 - 371
  • [23] Platinum resistance and sensitivity in recurrent/metastatic head and neck squamous cell carcinoma
    Horichi, Yuto
    Matsui, Hidetoshi
    Yamamura, Yuta
    Iwae, Shigemichi
    AURIS NASUS LARYNX, 2024, 51 (01) : 132 - 137
  • [24] A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Espinosa, E
    Zamora, P
    Millá, A
    Morales, S
    Molina, R
    Mira, M
    Barón, MG
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (12): : 1054 - 1059
  • [25] Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haddad, Robert, I
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 982 - 984
  • [26] A Study Using Ifosfamide and Etoposide in Patients with Cisplatin-refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Huang, Yu-Chung
    Chang, Peter Mu-Hsin
    Chen, Ming-Huang
    Chu, Pen-Yuan
    Tzeng, Cheng-Hwai
    Chang, Shyue-Yih
    Yang, Muh-Hwa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (05) : 630 - 636
  • [27] Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03
    Fayette, Jerome
    Guigay, Joel
    Le Tourneau, Christophe
    Degardin, Marian
    Peyrade, Frederic
    Neidhardt, Eve-Marie
    Sablin, Marie-Paule
    Even, Caroline
    Orlandini, Florence
    Juzyna, Beata
    Bellera, Carine
    ONCOTARGET, 2017, 8 (31) : 51830 - 51839
  • [28] A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    de Souza, Jonas A.
    Davis, Darren W.
    Zhang, Yujian
    Khattri, Arun
    Seiwert, Tanguy Y.
    Aktolga, Serdal
    Wong, Stuart J.
    Kozloff, Mark F.
    Nattam, Sreenivasa
    Lingen, Mark W.
    Kunnavakkam, Rangesh
    Stenson, Kerstin M.
    Blair, Elizabeth A.
    Bozeman, Jeffrey
    Dancey, Janet E.
    Vokes, Everett E.
    Cohen, Ezra E. W.
    CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2336 - 2343
  • [29] Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Kim, Moon Jin
    Kim, Sung Min
    Jung, Hyun Ae
    Hong, Jung Yong
    Chang, Won Jin
    Choi, Moon Ki
    Kim, Hye Soak
    Sun, Jong-Mu
    Park, Keunchil
    Ahn, Myung-Ju
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05) : 1107 - 1115
  • [30] Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma
    Weiss, Jared M.
    Bagley, Stephen
    Hwang, Wei-Ting
    Bauml, Joshua
    Olson, Juneko Grilley
    Cohen, Roger B.
    Hayes, David Neil
    Langer, Corey
    CANCER, 2016, 122 (15) : 2350 - 2355
12345